|
1
|
Bergstrom R, Sparen P and Adami HO: Trends
in cancer of the cervix uteri in Sweden following cytological
screening. Br J Cancer. 81:159–166. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gunnell AS, Ylitalo N, Sandin S, Spärén P,
Adami HO and Ripatti S: A longitudinal Swedish study on screening
for squamous cell carcinoma and adenocarcinoma: evidence of
effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev.
16:2641–2648. 2007. View Article : Google Scholar
|
|
3
|
Nobbenhuis MA, Walboomers JM, Helmerhorst
TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst
FJ, Kenemans P and Meijer CJ: Relation of human papillomavirus
status to cervical lesions and consequences for cervical-cancer
screening: a prospective study. Lancet. 354:20–25. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Muñoz N: Human papillomavirus and cancer:
the epidemiological evidence. J Clin Virol. 19:1–5. 2000.
|
|
5
|
Clifford GM, Smith JS, Aguado T and
Franceschi S: Comparison of HPV type distribution in high-grade
cervical lesions and cervical cancer: a meta-analysis. Br J Cancer.
89:101–105. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Walboomers JM, Jacobs MV, Manos MM, Bosch
FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N:
Human papillomavirus is a necessary cause of invasive cervical
cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bosch FX and Muñoz N: The viral etiology
of cervical cancer. Virus Res. 89:183–190. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
zur Hausen H: Papillomaviruses and cancer:
from basic studies to clinical application. Nat Rev Cancer.
2:342–350. 2002.PubMed/NCBI
|
|
9
|
Muñoz N, Bosch FX, de Sanjosé S, Herrero
R, Castellsagué X, Shah KV, Snijders PJ and Meijer CJ:
Epidemiologic classification of human papillomavirus types
associated with cervical cancer. N Engl J Med. 348:518–527.
2003.
|
|
10
|
Evander M, Edlund K, Gustafsson A, Jonsson
M, Karlsson R, Rylander E and Wadell G: Human papillomavirus
infection is transient in young women: a population-based cohort
study. J Infect Dis. 171:1026–1030. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Benton C, Shahidullah H and Hunter JAA:
Human papillomavirus in the immunosuppressed. Papillomavirus Rep.
3:23–26. 1992.
|
|
12
|
Stanley M: Immune responses to human
papillomavirus. Vaccine. 24(Suppl 1): S16–S22. 2006. View Article : Google Scholar
|
|
13
|
Song SH, Lee JK, Lee NW, Saw HS, Kang JS
and Lee KW: Interferon-γ (IFN-γ): a possible prognostic marker for
clearance of high-risk human papillomavirus (HPV). Gynecol Oncol.
108:543–548. 2008.
|
|
14
|
Coleman N, Birley HD, Renton AM, Hanna NF,
Ryait BK, Byrne M, Taylor-Robinson D and Stanley MA: Immunological
events in regressing genital warts. Am J Clin Pathol. 102:768–774.
1994.PubMed/NCBI
|
|
15
|
Kadish AS, Timmins P, Wang Y, Ho GY, Burk
RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R and Abadi M:
Regression of cervical intraepithelial neoplasia and loss of human
papillomavirus (HPV) infection is associated with cell-mediated
immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol
Biomarkers Prev. 11:483–488. 2002.
|
|
16
|
Griesser H, Sander H, Hilfrich R, Moser B
and Schenck U: Correlation of immunochemical detection of HPV L1
capsid protein in pap smears with regression of high-risk HPV
positive mild/moderate dysplasia. Anal Quant Cytol Histol.
26:241–245. 2004.PubMed/NCBI
|
|
17
|
Hilfrich R and Hariri J: Prognostic
relevance of human papillomavirus L1 capsid protein detection
within mild and moderate dysplastic lesions of the cervix uteri in
combination with p16 biomarker. Anal Quant Cytol Histol. 30:78–82.
2008.
|
|
18
|
Solomon D, Davey D, Kurman R, Moriarty A,
O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr and
Young N; Forum Group Members; Bethesda 2001 Workshop. The 2001
Bethesda System: terminology for reporting results of cervical
cytology. JAMA. 287:2114–2119. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Richart RM: Cervical intraepithelial
neoplasia. Pathol Annu. 8:301–328. 1973.PubMed/NCBI
|
|
20
|
Brismar S, Johansson B, Borjesson M, Arbyn
M and Andersson S: Follow-up after treatment of cervical
intraepithelial neoplasia by human papillomavirus genotyping. Am J
Obstet Gynecol. 201:17.e1–17e8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Melsheimer P, Kaul S, Dobeck S and Bastert
G: Immunocytochemical detection of HPV high-risk type L1 capsid
proteins in LSIL and HSIL as compared with detection of HPV L1 DNA.
Acta Cytol. 47:124–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Griesser H, Sander H, Walczak C and
Hilfrich RA: HPV vaccine protein L1 predicts disease outcome of
high-risk HPV+ early squamous dysplastic lesions. Am J Clin Pathol.
132:840–845. 2009.PubMed/NCBI
|
|
23
|
Luostarinen T, af Geijersstam V, Bjorge T,
Eklund C, Hakama M, Hakulinen T, Jellum E, Koskela P, Paavonen J,
Pukkala E, Schiller JT, Thoresen S, Youngman LD, Dillner J and
Lehtinen M: No excess risk of cervical carcinoma among women
seropositive for both HPV16 and HPV6/11. Int J Cancer. 80:818–822.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cuzick J, Clavel C, Petry KU, Meijer CJ,
Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni
P and Iftner T: Overview of the European and North American studies
on HPV testing in primary cervical cancer screening. Int J Cancer.
119:1095–1101. 2006. View Article : Google Scholar : PubMed/NCBI
|
